Harrow (HROW) announced that it has completed the acquisition of Melt Pharmaceuticals. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis ODT drug delivery platform. “The closing of the Melt acquisition marks a strategic expansion of Harrow’s portfolio and reinforces its commitment to delivering innovative therapies that improve patient outcomes,” the company said.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health’s Earnings Call: Strong Growth Amid Challenges
- Harrow price target raised to $66 from $64 at Ladenburg
- Harrow Health: Strong Growth Prospects and Strategic Market Expansion Drive Buy Rating
- Harrow Health’s Strong Financial Performance and Strategic Initiatives Justify Buy Rating with Revised Price Target
- Harrow price target raised to $69 from $64 at H.C. Wainwright